

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (date of earliest event reported): **June 6, 2023**

**vTv Therapeutics Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-37524**  
(Commission File No.)

**47-3916571**  
(IRS Employer  
Identification No.)

**3980 Premier Drive, Suite 310  
High Point, NC 27265**  
(Address of principal executive offices)

**(336) 841-0300**  
(Registrant's telephone number, including area code)

**NOT APPLICABLE**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value \$0.01 per share	VTVT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 6, 2023, vTv Therapeutics Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

- (1) Based on the following results of the voting, the Company’s stockholders elected the nominees listed below to the Company’s Board of Directors, each to serve for a term to expire at the Company’s 2024 annual meeting of stockholders or until their successors are duly elected and qualified:

Director Nominee	For	Withheld	Broker Non Votes
John A. Fry	65,554,590	245,544	10,687,845
Chandresh Harjivan	65,530,597	269,537	10,687,845
Keith Harris	65,281,995	518,139	10,687,845
Jonathan Isaacsohn	65,386,409	413,725	10,687,845
Hersh Kozlov	64,477,507	1,322,627	10,687,845
Fahed Al Marzooqi	65,413,332	386,802	10,687,845
Richard S. Nelson	65,280,700	519,434	10,687,845
Paul Sekhri	65,539,487	260,647	10,687,845
Howard L. Weiner	65,392,364	407,770	10,687,845

- (2) The Company’s stockholders approved on a nonbinding advisory basis the compensation paid to the Company’s named executive officers based upon the following results of the voting:

For	Against	Abstain	Broker Non Votes
64,740,672	911,509	147,953	10,687,845

- (3) The Company’s stockholders set the frequency of future nonbinding advisory votes on the compensation paid to the Company’s named executive officers as every three years based upon the following results of the voting:

1 Year	2 Years	3 Years	Abstain	Broker Non Votes
2,342,432	114,442	63,036,155	307,105.	10,687,845

Based upon the results of the voting, and consistent with the recommendation of the Board of Directors with regard to this proposal as set forth in the proxy materials for the Annual Meeting, the Company intends to conduct a non-binding advisory vote on the compensation of its named executive officers every three years until the next required vote regarding the frequency of advisory votes regarding the compensation of the company’s named executive officers.

- (4) The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified based on the following results of the voting:

For	Against	Abstain	Broker Non Votes
75,554,888	895,657	37,434	0

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

### **VTV THERAPEUTICS INC.**

By: /s/ Paul J. Sekhri  
Name: Paul J. Sekhri  
Title: President and Chief Executive Officer

Dated: June 8, 2023